Soo-Yeon Hwang

Dr. Soo-Yeon Hwang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2022 in EMBO Reports
Verified
Journal Article
Open access
SSSeung Hee Seo
Seung Hee Seo
SHSoo-Yeon Hwang
Soo-Yeon Hwang
SHSeohui Hwang
Seohui Hwang
SHSunjung Han
Sunjung Han
HPHyojin Park
Hyojin Park
YKYoungjoo Kwon
Youngjoo Kwon
Epithelial ovarian cancer (EOC) is one of the most lethal gynecological cancers despite a relatively low incidence. Angiogenesis, one of the hallmarks of cancer, is essential for the pathogenesis of EOC, which is related to the induction of angiogenic factors. We found that ELF3 was highly expressed in EOCs under hypoxia and functioned as a transcription factor for IGF1. The ELF3‐mediated increase in the secretion of IGF1 and VEGF promoted endothelial cell proliferation, migration, and EOC angiogenesis. Although this situation was much exaggerated under hypoxia, ELF3 silencing under hypoxia significantly attenuated angiogenic activity in endothelial cells by reducing the expression and secretion of IGF1 and VEGF. ELF3 silencing attenuated angiogenesis and tumorigenesis in ex vivo and xenograft mouse models. Consequently, ELF3 plays an important role in the induction of angiogenesis and tumorigenesis in EOC as a transcription factor of IGF1. A detailed understanding of the biological mechanism of ELF3 may both improve current antiangiogenic therapies and have anticancer effects for EOC.

11 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SHSoo-Yeon Hwang
Soo-Yeon Hwang
SCSeul-Ki Choi
Seul-Ki Choi
SSSeung Hee Seo
Seung Hee Seo
HJHyunji Jo
Hyunji Jo
JSJae-Ho Shin
Jae-Ho Shin
YKYoungjoo Kwon
Youngjoo Kwon
Trastuzumab (TZMB) is widely used as first line therapy for breast cancer (BC) patients overexpressing human epidermal growth factor receptor 2 (HER2). Despite its clinical benefits, many patients suffer from primary or secondary resistance to this drug within one year. As diverse molecular mechanisms occur contemporaneously during the resistance development, we focused on elucidating the role of heat shock protein 27 (HSP27) in TZMB-resistance, as this protein simultaneously regulates the function of diverse client molecules that are involved in the resistance mechanism. By extensively utilizing TZMB-refractory breast cancer cell lines transduced with diverse phosphovariants of HSP27, our study newly revealed that specific phosphorylation of HSP27 at S15 promoted its S78 phosphorylation and served as key mediator to promote direct interactions that increase the stability of HER2 and protein kinase B (AKT). This phosphorylation promoted nuclear translocation of HER2, enhancing the distinct nuclear function of HER2 that promoted AKT activation and cyclin D1 expression. Co-administration of TZMB and a functional inhibitor of HSP27, J2, significantly reduced the S15/78 phosphorylation of HSP27, which downregulated HER2 and its downstream signals, sensitizing TZMB-refractory cell, and JIMT1-xenograft mouse models to TZMB. Collectively, p-HSP27S15 could serve as a valuable predictive marker and also a therapeutic target for TZMB-resistance.

Verified
Journal Article
Open access
PDF file
KJKyung-Hwa Jeon
Kyung-Hwa Jeon
SPSeojeong Park
Seojeong Park
HJHae Jin Jang
Hae Jin Jang
SHSoo-Yeon Hwang
Soo-Yeon Hwang
ASAarajana Shrestha
Aarajana Shrestha
YKYoungjoo Kwon
Youngjoo Kwon
Castration-resistant prostate cancer (CRPC) is a clinical challenge in treatment because of its aggressive nature and resistance to androgen deprivation therapy. Topoisomerase II catalytic inhibitors have been suggested as a strategy to overcome these issues. We previously reported AK-I-190 as a novel topoisomerase II inhibitor. In this study, the mechanism of AK-I-190 was clarified using various types of spectroscopic and biological evaluations. AK-I-190 showed potent topoisomerase II inhibitory activity through intercalating into DNA without stabilizing the DNA-enzyme cleavage complex, resulting in significantly less DNA toxicity than etoposide, a clinically used topoisomerase II poison. AK-I-190 induced G1 arrest and effectively inhibited cell proliferation and colony formation in combination with paclitaxel in an androgen receptor–negative CRPC cell line. Our results confirmed that topoisomerase II catalytic inhibition inhibited proliferation and induced apoptosis of AR-independently growing prostate cancer cells. These findings indicate the clinical relevance of topoisomerase II catalytic inhibitors in androgen receptor-negative prostate cancer.

1 December 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SKSurendra Kunwar
Surendra Kunwar
SHSoo-Yeon Hwang
Soo-Yeon Hwang
PKPramila Katila
Pramila Katila
SPSeojeong Park
Seojeong Park
KJKyung-Hwa Jeon
Kyung-Hwa Jeon
ELEung-Seok Lee
Eung-Seok Lee

5 September 2025 in bioRxiv
Verified
Preprint
Open access
SHSoo-Yeon Hwang
Soo-Yeon Hwang
HNHelgi Nikolli
Helgi Nikolli
BYBelem Yoval-Sánchez
Belem Yoval-Sánchez
SYSieun Yang
Sieun Yang
PMPeter Martin
Peter Martin
JPJihye Paik
Jihye Paik
Resistance to Bruton’s tyrosine kinase inhibitors (BTKi) remains a major therapeutic challenge in B-cell malignancies, limiting treatment durability. Here, we identify ferroptosis suppression as a central mechanism of BTKi resistance in mantle cell lymphoma (MCL). Aberrant BRG1 activity protects cells from BTKi-induced ferroptosis by restricting reactive oxygen species (ROS) and labile iron. Mechanistically, BRG1 promotes resistance through both BTK-dependent survival signaling and a BTK-independent transcriptional program. The latter is mediated by BRG1-driven induction of MEF2B, which upregulates NDUFA4L2 to inhibit mitochondrial respiration, thereby blocking mitochondria-dependent ferroptosis. Pharmacologic inhibition of BRG1 disrupts these programs, restoring ferroptotic sensitivity and synergizing with BTKi across resistant MCL models. Together, these findings establish BRG1 as a central regulator of therapy resistance and provide a rationale for co-targeting BRG1 and BTK as a therapeutic strategy for B-cell malignancies.

2 July 2026 in Nature Communications
Verified
Journal Article
Open access
SHSoo-Yeon Hwang
Soo-Yeon Hwang
XHXiangao Huang
Xiangao Huang
HNHelgi Nikolli
Helgi Nikolli
BYBelem Yoval-Sánchez
Belem Yoval-Sánchez
SYSieun Yang
Sieun Yang
JPJihye Paik
Jihye Paik
Resistance to Bruton’s tyrosine kinase inhibitors (BTKi) remains a major therapeutic challenge in B-cell malignancies. Here, we identify chromatin remodeler BRG1-mediated suppression of ferroptosis as a central mechanism of BTKi resistance in mantle cell lymphoma (MCL), in which aberrant BRG1-dependent transcription program protects cells from BTKi-induced ferroptosis by restricting reactive oxygen species (ROS) and labile iron. Mechanistically, BRG1 promotes resistance through regulation of both BTK-dependent survival signaling and a BTK-independent transcriptional program. The latter is mediated by BRG1-driven induction of MEF2B, which upregulates atypical mitochondrial complex I subunit NDUFA4L2. Increased NDUFA4L2 restricts cellular respiration, preemptively limiting mitochondrial ROS generation and activating AMPK signaling, together reducing susceptibility to lipid peroxidation and ferroptosis. Pharmacologic inhibition of BRG1 disrupts these programs, restoring ferroptotic sensitivity and synergizing with BTKi across resistant MCL models. Together, our study establishes BRG1 as a central regulator of BTKi resistance and provides a rationale for co-targeting BRG1 and BTK as a therapeutic strategy for B-cell malignancies.